AstraZeneca and Tessella will offer their PreDICT data platform for use across the pharmaceutical industry.
AstraZeneca’s PreDICT (Preclinical Data Integration and Capture Tool) platform, developed in partnership with Abingdon, UK-based data analysis firm Tessella, captures and analyses preclinical pharmacokinetic, pharmacodynamic and efficacy data. It ensures data integrity and allows scientists to rapidly find, integrate and share in vivo data sets for the prediction of optimal doses and schedules in clinical trials.
Key features of PreDICT include: flexible study templates that capture in-depth experiment detail at all study stages; automated data processing and integration; a single, central repository and search tool to enable access to an organisation’s entire preclinical data capture; standardised and automated study analysis in a configurable calculation engine; output of combined data sets from multiple studies into Excel- and Spotfire-compatible formats to enable data visualisation.
AstraZeneca said it has seen significant benefits from using the platform, including:
- Assured data integrity for thousands of preclinical studies
- Rapid integration of pharmacokinetic (PK) and pharmacodynamic (PD) data
- 30% time saving for modellers producing PK/PD models to understand and predict exposure-response relationships
- Reduction of modelling outsourcing costs by up to 20%
- Time savings from simplified workflows of 1.5–2 days across every study in bioscience and DMPK
- Significant improvements in data quality and confidence in data
'Many drug discovery organisations have a culture where capture, storage and sharing of complex data sets is spreadsheet-based, which leads to many practical problems,' said Alan Bell, Director of Life Sciences at Tessella.
'These data sets are pivotal to the development of every new drug and, compounding the challenges, the studies are generated and modelled by multiple scientific groups, making data and knowledge management and timely communication incredibly difficult. AstraZeneca has proactively addressed these issues through the development of PreDICT.'
Susan Galbraith, SVP of Oncology IMED from AstraZeneca, added: 'We’ve used PreDICT for more than 150 projects and the data capture and analysis has involved the consideration of more than three and a half million result data points. PreDICT helps us analyse and visualise data quickly so that we can use it to deliver meaningful clinical benefits.'
